Information  X 
Enter a valid email address

K.S. Biomedix Hldgs (FOGC)

  Print   

Thursday 25 April, 2002

K.S. Biomedix Hldgs

RE: Clinical Trials Programme

K.S. Biomedix Holdings PLC
25 April 2002


Embargoed until 0700                                               25 April 2002


KS Biomedix Holdings plc                                Tel: +44 (0) 1483 307500
Dr Steven Powell, Chief Executive Officer

Weber Shandwick Square Mile                           Tel:  +44 (0) 20 7950 2800
Kevin Smith
Susanne Walker



               KS Biomedix To Commence Phase I/II Clinical
                       Trials For Pancreatic Cancer

Guildford, UK... KS Biomedix Holdings plc ('KSB' or 'the Company') (LSE: KSB)
today announces further significant progress in the clinical development of KSB
303, the Group's first in-house developed monoclonal antibody.  Having now
analysed data from a successful Phase I imaging study in colorectal cancer
patients, KSB is announcing the extension of the KSB303 clinical trials
programme to target a further indication, pancreatic cancer.

KSB303 is a radiolabelled high affinity chimeric monoclonal antibody being
developed for a range of cancer indications.  KSB303's ability to bind to the
target antigen for prolonged periods should result in low dosing, few side
effects and a wide therapeutic window.

The imaging study for KSB303 has been conducted in Malaysia and Belgium.  Data
from this study are very promising with the antibody being shown to localise
effectively at colorectal cancer metastases (secondary tumours) with prolonged
retention of the antibody in tumour sites.  There was rapid clearance of
circulating antibody not bound at the tumour.  Using gamma camera and SPECT
imaging techniques the antibody could be seen to remain localised at the surface
of the secondary tumours for as long as eight days after dosing thereby proving
itself to be an effective means of targeting these tumour types.  Significantly,
no human anti-sheep antibody ('HASA') response to the antibody has been recorded
to date and there have been no serious adverse drug reactions indicating that
the antibody has a good safety and tolerance profile in this initial study.

In the light of these positive data, KS Biomedix now intends to progress the
development of KSB303 as a therapeutic agent in carcino-embryonic-antigen ('CEA
') expressing solid tumours in a series of Phase I/II clinical trials.  The
first therapeutic clinical trial of KSB303 will be in patients with advanced
pancreatic cancer.  Phase I/II trials in colorectal cancer are also planned.

The Phase I/II trial for pancreatic cancer will be a dose escalation study to
assess the safety, tolerability and pharmacokinetics of the antibody in patients
with advanced disease.

Pancreatic cancer is a common malignancy with approximately 38,000 new cases per
year in Europe and 30,000 cases in the USA.  The majority of patients present
with advanced disease and, with current therapeutic approaches, the prognosis in
these patients is very poor with an overall long-term survival rate of only
0.4%.

The Phase I/II study for pancreatic cancer will be conducted in UK clinical
centres and the Principal Investigator will be Professor John Neoptolemos,
Professor of Surgery at the University of Liverpool.  Professor Neoptolemos is
currently the President of the International Association of Pancreatology and
Co-secretary of the European Study Group for Pancreatic Cancer ('ESPAC').  The
study is scheduled to commence in the third quarter of the current calendar
year.  Further therapeutic studies in other CEA expressing solid tumours,
including colorectal cancer, are planned in the first half of 2003.

Steven Powell, Chief Executive Officer, commented: 'The very encouraging data
from the Phase 1 study have confirmed our belief that KSB303's high affinity
properties make it a highly suitable drug candidate for the treatment of cancer.
  We are now driving our clinical programme to accelerate the development of our
first high affinity antibody based therapeutic.  Pancreatic cancer is an
indication that is poorly served by current drug treatments and represents a
significant potential worldwide market valued in excess of  £350m per annum.  We
believe that KSB303's ability to bind to the target antigen for prolonged
periods will be an equally valuable property for this indication, promising
pancreatic cancer patients a more effective treatment with fewer side effects.'

                                    - Ends -



Notes to Editors


KS Biomedix Holdings Plc (Guildford, UK) is a biopharmaceutical company
headquartered in the UK that is developing a broad late-stage pipeline of drugs
for a range of cancer indications and inflammatory disease. In addition, it has
a number of technology platforms based on its range of receptor-based targeting
technologies one of which is KSB's super high-affinity monoclonal antibodies
(SMAs).  The Company has eight products in or about to commence clinical trials
including TransMID-107RTM for the treatment of adult, recurrent, inoperable
high-grade gliomas (brain tumours), KSB302 which is in Phase IIb clinical trials
for the treatment of rheumatoid arthritis and KSB303, an anti-CEA antibody for
the diagnosis and treatment of cancer.

KS Biomedix was founded in 1993 and floated on the Alternative Investment Market
of the London Stock Exchange in 1995.  The Company joined the Official List of
the London Stock Exchange in 1998.

For more information please see www.ksbiomedix.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                                                                 

a d v e r t i s e m e n t